Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — Q2 FY22 Earnings Presentation
24 slides from Cohance Lifesciences's earnings presentation, November 2021
Slide 1: Suven Pharma Earnings Presentation Q2 & H1FY22
SUVEN PHARMA Earnings Presentation Q2 & H1FY22
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Table of Contents
4 14 Table of Operation & Financial Company Background Contents Performance Q2FY22 3
Slide 4: Operation & Financial Performance Q2FY22
Operation & Financial Performance Q2FY22 4
Slide 5: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other 137.34 Ser vices 144.17 144.35 25 19.3 68.22 Q2FY21 Q2FY22 Q2FY21 Q2FY22 Q2FY21 Q2FY22 Note: Figures in Rs. Crore 5
Slide 6: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other 297.74 Ser vices 222.21 269.05 44.84 44.84 161.73 H1FY21 H1FY22 H1FY21 H1FY22 H1FY21 H1FY22 Note: Figures in Rs. Crore 6
Slide 7: Financial Snapshot
Financial Snapshot Q2FY22 H1FY22 Growth in Growth in Growth in Revenue EBITDA PAT 42.73% 62.99% 76.33% 26.40% 30.11% 34.17% 7
Slide 8: Key Ratios
Key Ratios Q2FY22 H1FY22 Growth in EBITDA to PAT to EBIT Income Income 44.48% 47.19% 33.95% 43.08% 46.07% 32.29% 8
Slide 9: Financials Q2FY22
Financials Q2FY22 Revenue EBIDTA PAT EPS 3,393 1,601 4.5 1,152 2,696 2,377 1,204 814 3.2 RUPEES MN RUPEES MN RUPEES MN 982 653 2.6 RUPEES Q2FY21 Q1FY22 Q2FY22 Q2FY21 Q1FY22 Q2FY22 Q2FY21 Q1FY22 Q2FY22 Q2FY21 Q1FY22 Q2FY22 9
Slide 10: Financials H1FY22
Financials H1FY22 Revenue EBIDTA PAT EPS 6,089 2,805 1,966 7.7 4,817 2,156 1,466 5.8 RUPEES MN RUPEES MN RUPEES MN RUPEES H1FY21 H1FY22 H1FY21 H1FY22 H1FY21 H1FY22 H1FY21 H1FY22 10
Slide 11: Financials Q2FY22
Financials Q2FY22 EBITDA Margin (%) PAT Margin (%) 47% 45% 41% 34% 30% 27% Q2FY21 Q1FY22 Q2FY22 Q2FY21 Q1FY22 Q2FY22 11
Slide 12: Financials H1FY22
Financials H1FY22 EBITDA Margin (%) PAT Margin (%) 45% 46% 30% 32% H1FY21 H1FY22 H1FY21 H1FY22 12
Slide 13: Financial Table – Q2 FY22
Financial Table – Q2 FY22 Quarter ended Period ended 30-Sep-21 30-Jun-21 30-Sep-20 30-Sep-21 30-Jun-21 Revenue 3,393.23 2,695.84 2,377.45 6,089.08 4,817.16 EBITDA 1,601.10 1,203.99 982.30 2,805.10 2,155.91 EBITDA Margin 47.19% 44.66% 41.32% 46.07% 44.75% EBIT 1,509.33 1,114.06 907.30 2,623.39 2,010.
Slide 14: Company Background
Company Background PHARMA
Slide 15: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 15
Slide 16: Brief Profile
Brief Profile BUSINESS OVERVIEW o Integrated CDMO KEY STRENGTHS company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Standalone Revenues, EBIT and PAT process research & across the entire CDMO of Rs 60,891 lacs, Rs 26,234 lacs and
Slide 17: Suven is an integrated Contract Development and Manufacturing Operations company
Suven is an integrated Contract Development and Manufacturing Operations company Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since our founding in
Slide 18: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 18 18
Slide 19: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 19
Slide 20: Business Drivers
Business Drivers Industry Relationship An integrated research service provider with Leveraging on unmatched capabilities research capabilities Present across the to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 20
Slide 21: Business Drivers
Business Drivers Execution Capabilities Over 90% of Working with revenues from innovator companies regulated in developed markets markets having stringent regulations – Long term reflection of our commercial supply with the launch of research skills Repeat business owing to long product by global st
Slide 22: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 23: Contact
Contact For queries and requests, please contact: Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Email: info@suvenpharm.com For more info: www.suvenpharm.com # 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA. Gavin Desa / Risha
Slide 24: Thank You
Thank You 6 SUVEN PHARMA
Suven Pharmaceuticals — Q2 FY22 Earnings Presentation on 6ix